Limited coverage drugs – cysteamine ophthalmic solution
Publication date: February 28, 2022
|
Generic name |
cysteamine ophthalmic solution |
|
|---|---|---|
|
Strength |
0.37 %/w/w (3.8 mg/mL) |
|
|
Form |
ophthalmic viscous solution |
|
|
Special Authority criteria |
Approval period |
|---|---|
|
For the treatment of corneal cystine crystal deposits in patients with cystinosis, also known as ocular cystinosis. The patient must be under the care of an ophthalmologist experienced in the management of the ocular manifestations of cystinosis. Special Authority request must be submitted by a specialist with expertise with treating ocular cystinosis. |
1 year |
Practitioner exemptions
- None
Special notes
- None